Lumida
/EYPT
⌘K
EyePoint Pharmaceuticals Inc

EyePoint Pharmaceuticals Inc

EYPT
$4.34USD↓-4.82%-0.22 today

MARKET CAP

374.2M

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$4 – $5

52W RANGE

$4
$19

AI Summary

Stalk
Sell NowMedium

Following the sharp reversal from range highs and breakdown below key EMAs and the 50-day SMA on heavy volume, EYPT now enters a medium-term bearish phase. Price has failed dynamic support at the 9/20/50 EMAs and vaulted through lateral lows without signs of exhaustion, prompting immediate sell-side participation. Despite extreme oversold readings, no reversal structure is evident. Speculative strategy demands high-discipline selling into relief bounces.

  • ↑Analysts at Chardan and Cantor project 349–407% upside.
  • ↑Phase 3 DURAVYU topline data expected August 2026, key catalyst.
  • ↓Q2 2026 net loss of $1.09/share underscores weak profitability.
Full analysis →

The case for & against

Bull & Bear analysis

Bullish

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) is a biotechnology company that focuses on developing innovative therapeutics for serious retinal diseases. The company operates primarily in the ophthalmology sector, with its flagship product, DURAVYU, targeting the treatment of wet age-related macular degeneration and other serious retina-related conditions. EyePoint's product pipeline and therapeutic advancements place it at the forefront of the ophthalmology market, which is benefiting from increasing prevalence of retinal diseases and an aging population.

Bull says

  • ↑Analysts at Chardan and Cantor project 349–407% upside.
  • ↑Phase 3 DURAVYU topline data expected August 2026, key catalyst.
  • ↑High institutional ownership underlines strong investor confidence.
  • ↑Strong momentum and growth factors support price upside.
  • ↑Q2 2026 revenue beat at $0.51M; cash runway into Q4 2027.
  • ↑New hiring inducement grants bolster R&D and pipeline support.

Bear says

  • ↓Q2 2026 net loss of $1.09/share underscores weak profitability.
  • ↓Negative earnings yield and downward revisions risk valuation.
  • ↓Elevated leverage exposure may strain financial stability.
  • ↓Surge in put option activity reflects bearish bets.
  • ↓Planned stock‐option grants could dilute existing shareholders.
  • ↓High volatility risk may deter cautious investors.

Investment themes with EYPT

Pharmaceuticals↓ -0.48%

Drug development driving global healthcare solutions

JNJ · LLY · RPRX

Earnings Call · Q1 2026 · Mgmt. Guidance

Updated 05-10-2026neutral

Transcript signals

Bull points

  • We continue to expect that our current cash position will enable us to fund operations into the fourth quarter of 2027 beyond key milestones for the Phase III wet AMD program expected later this year.
  • we're pleased with I-Point's progress so far in 2026 and remain well capitalized to deliver DuraView through key value driving milestones in the two largest retinal disease markets.
  • We continue to expect that our current cash position will enable us to fund operations into the fourth quarter of 2027 beyond key milestones for the Phase III wet AMD program expected later this year.

Bear points

  • Total net revenue was $0.7 million compared to $24.5 million for the quarter ended March 31, 2025. The decrease was primarily driven by the recognition of remaining deferred revenue related to the company's agreements in the second quarter of 2023 for the license of Utique Product Rights.
  • net loss was 85 million or 99 cents per share compared to a net loss of 45 million or 65 cents per share for the prior year period.
  • Total net revenue was $0.7 million compared to $24.5 million for the quarter ended March 31, 2025. The decrease was primarily driven by the recognition of remaining deferred revenue related to the company's agreements in the second quarter of 2023 for the license of Utique Product Rights.
Read full transcript analysis ›